90 related articles for article (PubMed ID: 19626629)
1. Evidence-based guidelines to optimize the selection of antibody panels in cytopathology: pleural effusions with malignant epithelioid cells.
Westfall DE; Fan X; Marchevsky AM
Diagn Cytopathol; 2010 Jan; 38(1):9-14. PubMed ID: 19626629
[TBL] [Abstract][Full Text] [Related]
2. Effusion cytology in the diagnosis of malignant epithelioid and biphasic pleural mesothelioma.
Sherman ME; Mark EJ
Arch Pathol Lab Med; 1990 Aug; 114(8):845-51. PubMed ID: 2375659
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemistry and molecular diagnostics of pleural malignant mesothelioma.
Betta PG; Magnani C; Bensi T; Trincheri NF; Orecchia S
Arch Pathol Lab Med; 2012 Mar; 136(3):253-61. PubMed ID: 22372901
[TBL] [Abstract][Full Text] [Related]
4. Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma.
Mimura T; Ito A; Sakuma T; Ohbayashi C; Yoshimura M; Tsubota N; Okita Y; Okada M
Cancer; 2007 Mar; 109(5):933-8. PubMed ID: 17279584
[TBL] [Abstract][Full Text] [Related]
5. The diagnostic utility of D2-40 for malignant mesothelioma versus pulmonary carcinoma with pleural involvement.
Saad RS; Lindner JL; Lin X; Liu YL; Silverman JF
Diagn Cytopathol; 2006 Dec; 34(12):801-6. PubMed ID: 17115439
[TBL] [Abstract][Full Text] [Related]
6. [Diagnostic value of the combined determination of carcinoembryonic antigen (CEA) in pleural effusion and serum with an enzyme immunoassay (EIA). Sensitivity, specificity and relation to tumor type].
Klech H; Rona G; Hutter C; Bayer PM; Kummer F
Wien Klin Wochenschr; 1986 Sep; 98(17):564-73. PubMed ID: 3020811
[TBL] [Abstract][Full Text] [Related]
7. Cytogenetic analysis of effusions from malignant mesothelioma. A diagnostic adjunct to cytology.
Granados R; Cibas ES; Fletcher JA
Acta Cytol; 1994; 38(5):711-7. PubMed ID: 8091903
[TBL] [Abstract][Full Text] [Related]
8. The value of calretinin and cytokeratin 5/6 as markers for mesothelioma in cell block preparations of serous effusions.
Shield PW; Koivurinne K
Cytopathology; 2008 Aug; 19(4):218-23. PubMed ID: 17916095
[TBL] [Abstract][Full Text] [Related]
9. The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions.
Illei PB; Ladanyi M; Rusch VW; Zakowski MF
Cancer; 2003 Feb; 99(1):51-6. PubMed ID: 12589646
[TBL] [Abstract][Full Text] [Related]
10. Accuracy and reproducibility of pleural effusion cytology.
Fassina A; Fedeli U; Corradin M; Da Frè M; Fabbris L
Leg Med (Tokyo); 2008 Jan; 10(1):20-5. PubMed ID: 17702624
[TBL] [Abstract][Full Text] [Related]
11. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions.
Bassarova AV; Nesland JM; Davidson B
Am J Surg Pathol; 2006 Jul; 30(7):878-82. PubMed ID: 16819331
[TBL] [Abstract][Full Text] [Related]
12. [Significance of combining detection of E-cadherin, carcinoembryonic antigen, and calretinin in cytological differential diagnosis of serous effusion].
Su XY; Li GD; Liu HB; Jiang LL
Ai Zheng; 2004 Oct; 23(10):1185-9. PubMed ID: 15473932
[TBL] [Abstract][Full Text] [Related]
13. Scoring system for differential diagnosis of malignant mesothelioma and reactive mesothelial cells on cytology specimens.
Kimura N; Dota K; Araya Y; Ishidate T; Ishizaka M
Diagn Cytopathol; 2009 Dec; 37(12):885-90. PubMed ID: 19572412
[TBL] [Abstract][Full Text] [Related]
14. h-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary.
Comin CE; Saieva C; Messerini L
Am J Surg Pathol; 2007 Aug; 31(8):1139-48. PubMed ID: 17667535
[TBL] [Abstract][Full Text] [Related]
15. The value of anti-calretinin antibody in the differential diagnosis of normal and reactive mesothelia versus metastatic tumors in effusion cytology.
Nagel H; Hemmerlein B; Ruschenburg I; Hüppe K; Droese M
Pathol Res Pract; 1998; 194(11):759-64. PubMed ID: 9842634
[TBL] [Abstract][Full Text] [Related]
16. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids.
Politi E; Kandaraki C; Apostolopoulou C; Kyritsi T; Koutselini H
Diagn Cytopathol; 2005 Mar; 32(3):151-5. PubMed ID: 15690338
[TBL] [Abstract][Full Text] [Related]
17. [Cytological exam of the pleural fluid in the diagnosis of neoplastic pleuritis. Cases contribution].
Vignale L; Galli G; Rossi PC; Parentini GC
Minerva Med; 1990 Jun; 81(6):455-9. PubMed ID: 2359501
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma.
Kushitani K; Takeshima Y; Amatya VJ; Furonaka O; Sakatani A; Inai K
Pathol Int; 2007 Apr; 57(4):190-9. PubMed ID: 17316414
[TBL] [Abstract][Full Text] [Related]
19. Mammaglobin and CRxA-01 in pleural effusion cytology: potential utility of distinguishing metastatic breast carcinomas from other cytokeratin 7-positive/cytokeratin 20-negative carcinomas.
Ciampa A; Fanger G; Khan A; Rock KL; Xu B
Cancer; 2004 Dec; 102(6):368-72. PubMed ID: 15558786
[TBL] [Abstract][Full Text] [Related]
20. [Clinical evaluation and tissue distribution of CA125 in patients with pleural effusion].
Tomita Y
Igaku Kenkyu; 1989 Nov; 59(3):90-6. PubMed ID: 2639592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
